CUMBERLAND PHARMACEUTICALS INC

Cumberland Pharmaceuticals announced a strategic transaction to divest its portfolio of FDA-approved brands to Apotex Inc. for $100 million in cash, aiming to sharpen its focus on developing high-value product candidates. For the first quarter of 2026, the company reported net revenues of $9.1 million and a net loss of $3.3 million. Additionally, Cumberland provided updates on its development pipeline, including breakthrough Phase II results for ifetroban in Duchenne muscular dystrophy and FDA Fast Track Designation for the candidate.

Cumberland Pharmaceuticals Inc. has entered into a strategic transaction to integrate its commercial products with an affiliate of Apotex Inc. Apotex will acquire several FDA-approved products, including Acetadote and Caldolor, for $100 million. Cumberland will retain its Cumberland Emerging Technologies assets and ifetroban product candidates, intending to focus on their development. The deal, unanimously approved by Cumberland's board, is subject to shareholder approval and other customary closing conditions.